Additionally, some researchers have employed engineered oncolytic viruses (OVs) to stimulate tumor cell chemokine production, as demonstrated by intravenous delivery of CXCL11-modified oncolytic vaccinia virus to a mouse tumor model, which resulted in an increased intratumoral CXCL11 concentration and thus high CAR T-cell infiltration (161). This evidence concerns the gene CXCL11 and neoplasm.